Insulet Corporation to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 7, 2008
BEDFORD, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD), the leader in wearable insulin pump technology with its OmniPod® Insulin Management System, today announced that Duane DeSisto, Chief Executive Officer, will participate in the Merrill Lynch Global Pharmaceutical and Medical Device Conference. Mr. DeSisto is scheduled to present an overview of the Company at 2:20 p.m. Eastern Time on Thursday, February 7, 2008 at The Grand Hyatt at Park Avenue in New York.
During the conference presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of the presentation during the event, please visit: http://investors.insulet.com. A replay of the webcast will be available for 14 days.
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully- automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.
Stephanie Marks for Insulet Corporation
SOURCE Insulet Corporation
Web site: http://investors.insulet.com